Compare ALLO & NOAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLO | NOAH |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 653.4M |
| IPO Year | 2018 | 2010 |
| Metric | ALLO | NOAH |
|---|---|---|
| Price | $2.06 | $10.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 2 |
| Target Price | $8.35 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 7.8M | 69.2K |
| Earning Date | 05-07-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 5.66% |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | $5.71 |
| P/E Ratio | ★ N/A | $13.29 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $9.53 |
| 52 Week High | $4.46 | $12.84 |
| Indicator | ALLO | NOAH |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 47.62 |
| Support Level | $1.85 | $9.83 |
| Resistance Level | $2.36 | $10.84 |
| Average True Range (ATR) | 0.13 | 0.28 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 74.12 | 54.01 |
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.